1. Scrip
  2. >>COVID-19

Sanofi CEO Takes Not-So-Slow And Steady Approach To COVID-19 Vaccines

'It's not a race between companies, it's a race against an enemy'

 
• By Kevin Grogan

Pfizer and BioNTech may be first out of the gate with robust results for a COVID-19 vaccine but amid all the excitement, Paul Hudson has issued a timely reminder that multiple vaccines will be needed to meet the huge demand.

Paul Hudson
Paul Hudson • Source: Sanofi

With expectations soaring that a COVID-19 vaccine is within reach following an interim Phase III analysis showing that Pfizer Inc. and BioNTech SE’s candidate was 90% effective in protecting people from transmission of the virus, Sanofi CEO Paul Hudson has stressed that no one company will be able to make enough vaccine to be able to solve the challenges the world faces.

Hudson was speaking at the Financial Times global pharmaceuticals and biotechnology conference on 9 November and made his comments literally minutes before the news wires crackled with the promising data on Pfizer/BioNTech's mRNA-based COVID-19 vaccine BNT162b2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.